Study of CVN424 in Parkinson's Disease Patients With Motor Fluctuations

PHASE2CompletedINTERVENTIONAL
Enrollment

136

Participants

Timeline

Start Date

December 2, 2019

Primary Completion Date

November 6, 2021

Study Completion Date

December 13, 2021

Conditions
Parkinson Disease
Interventions
DRUG

CVN424 Low Dose

CVN424

DRUG

CVN424 High Dose

CVN424

DRUG

Placebo

Placebo

Trial Locations (21)

10003

New York Neurology Associates, New York

27612

M3 Wake Research, Raleigh

29615

Prisma Health, Greenville

30328

NeuroTrials Research, Inc., Atlanta

32127

Accel Research Site - Brain and Spine Institute of Port Orange, Port Orange

32792

Charter Research, Winter Park

33122

Premier Clinical Research Institute, Miami

33486

Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton

33613

USF Parkinson's Disease and Movement Disorders Center, Tampa

33980

Parkinson's Disease Treatment Center of SW Florida, Port Charlotte

34209

Nova Clinical Research, Bradenton

43235

Optimed Research Ltd, Columbus

45459

Neurology Diagnostics Inc, Dayton

48334

Quest Research Institute, Farmington Hills

66160

Parkinson's Disease and Movement Disorder Center, Kansas City

78681

Central Texas Neurology Consultants, Round Rock

90806

Collaborative Neuroscience Network, LLC, Long Beach

91105

SC3 Research - Pasadena, Pasadena

99202

Inland Northwest Research, LLC, Spokane

02131

Boston Clinical Trials, Roslindale

08755

Bio Behavioral Health, Toms River

All Listed Sponsors
lead

Cerevance Beta, Inc.

INDUSTRY

NCT04191577 - Study of CVN424 in Parkinson's Disease Patients With Motor Fluctuations | Biotech Hunter | Biotech Hunter